BMY vs. MKC
BMY (Bristol-Myers Squibb Company) and MKC (McCormick & Company, Incorporated) are both stocks. BMY operates in Drug Manufacturers - General (Healthcare), while MKC operates in Packaged Foods (Consumer Defensive). Over the past 10 years, BMY returned 1.00%/yr vs 1.82%/yr for MKC. At a 0.24 correlation, their price movements are largely independent.
Performance
BMY vs. MKC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BMY achieves a 8.27% return, which is significantly higher than MKC's -27.49% return. Over the past 10 years, BMY has underperformed MKC with an annualized return of 1.00%, while MKC has yielded a comparatively higher 1.82% annualized return.
BMY
- 1D
- 0.40%
- 1M
- 0.23%
- YTD
- 8.27%
- 6M
- 11.43%
- 1Y
- 20.57%
- 3Y*
- 0.45%
- 5Y*
- 0.73%
- 10Y*
- 1.00%
MKC
- 1D
- -0.57%
- 1M
- 5.61%
- YTD
- -27.49%
- 6M
- -25.55%
- 1Y
- -31.93%
- 3Y*
- -16.44%
- 5Y*
- -9.29%
- 10Y*
- 1.82%
BMY vs. MKC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 8.27% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
MKC McCormick & Company, Incorporated | -27.49% | -8.33% | 13.97% | -15.68% | -12.65% | 2.67% | 14.70% | 23.65% | 39.01% | 11.34% |
Correlation
The correlation between BMY and MKC is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.34 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.33 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since Mar 26, 1990 | 0.24 |
Fundamentals
BMY:
$116.75B
MKC:
$13.19B
BMY:
$3.57
MKC:
$6.10
BMY:
16.02
MKC:
8.02
BMY:
0.91
MKC:
5.83
BMY:
2.40
MKC:
1.85
BMY:
5.82
MKC:
1.89
BMY:
$48.48B
MKC:
$7.11B
BMY:
$33.33B
MKC:
$2.70B
BMY:
$13.34B
MKC:
$1.22B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. MKC — Risk / Return Rank
BMY
MKC
BMY vs. MKC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and McCormick & Company, Incorporated (MKC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BMY | MKC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.88 | ||
| Sortino ratioReturn per unit of downside risk | +2.88 | ||
| Omega ratioGain probability vs. loss probability | 1.14 | 0.80 | +0.33 |
| Calmar ratioReturn relative to maximum drawdown | 1.53 | -0.85 | +2.38 |
| Martin ratioReturn relative to average drawdown | 3.32 | -1.69 | +5.01 |
Loading charts...
Drawdowns
BMY vs. MKC - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, which is greater than MKC's maximum drawdown of -52.02%. Use the drawdown chart below to compare losses from any high point for BMY and MKC.
Loading charts...
Drawdown Indicators
| BMY | MKC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -52.02% | -20.01% |
Max Drawdown (1Y)Largest decline over 1 year | -12.05% | -39.50% | +27.45% |
Max Drawdown (3Y)Largest decline over 3 years | -36.85% | -47.65% | +10.80% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -52.02% | +4.35% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -52.02% | +4.35% |
Current DrawdownCurrent decline from peak | -17.79% | -48.49% | +30.70% |
Average DrawdownAverage peak-to-trough decline | -22.38% | -11.03% | -11.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.34% | 19.92% | -13.58% |
Volatility
BMY vs. MKC - Volatility Comparison
Bristol-Myers Squibb Company (BMY) has a higher volatility of 8.22% compared to McCormick & Company, Incorporated (MKC) at 6.12%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than MKC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BMY | MKC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.22% | 6.12% | +2.10% |
Volatility (6M)Calculated over the trailing 6-month period | 18.18% | 23.28% | -5.10% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.08% | 28.06% | -0.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.02% | 24.34% | -0.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.29% | 24.17% | +1.12% |
Dividends
BMY vs. MKC - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 4.38%, more than MKC's 3.80% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.38% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
MKC McCormick & Company, Incorporated | 3.80% | 2.69% | 2.24% | 2.32% | 1.81% | 1.44% | 1.68% | 1.37% | 1.53% | 1.89% | 1.89% | 1.91% |
Financials
BMY vs. MKC - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and McCormick & Company, Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. MKC - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
MKC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, McCormick & Company, Incorporated reported a gross profit of 708.90M and revenue of 1.87B. Therefore, the gross margin over that period was 37.8%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
MKC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, McCormick & Company, Incorporated reported an operating income of 227.50M and revenue of 1.87B, resulting in an operating margin of 12.1%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
MKC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, McCormick & Company, Incorporated reported a net income of 1.02B and revenue of 1.87B, resulting in a net margin of 54.2%.
Frequently Asked Questions
BMY and MKC have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (8.22%) compared to MKC (6.12%). In terms of maximum drawdown, BMY dropped -72.03% vs MKC's -52.02%.
BMY currently has the higher Sharpe Ratio (0.68 vs -1.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BMY and MKC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer